Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection

Kasha P Singh; Jennifer M Zerbato; Wei Zhao; Sabine Braat; Claire Deleage; G Surekha Tennakoon; Hugh Mason; Ashanti Dantanarayana; Ajantha Rhodes; Jake W Rhodes; Joe Torresi; Andrew N Harman; Peter A Revill; Megan Crane; Jacob D Estes; Anchalee Avihingsanon; Sharon R Lewin; Jennifer Audsley

Journal article

Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection

Kasha P Singh, Jennifer M Zerbato, Wei Zhao, Sabine Braat, Claire Deleage, G Surekha Tennakoon, Hugh Mason, Ashanti Dantanarayana, Ajantha Rhodes, Jake W Rhodes, Joe Torresi, Andrew N Harman, Peter A Revill, Megan Crane, Jacob D Estes, Anchalee Avihingsanon, Sharon R Lewin, Jennifer Audsley

PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2020

DOI: 10.1371/journal.ppat.1008744

Download PDF

Abstract

In HIV-hepatitis B virus (HBV) co-infection, adverse liver outcomes including liver fibrosis occur at higher frequency than in HBV-mono-infection, even following antiretroviral therapy (ART) that suppresses both HIV and HBV replication. To determine whether liver disease was associated with intrahepatic or circulating markers of inflammation or burden of HIV or HBV, liver biopsies and blood were collected from HIV-HBV co-infected individuals (n = 39) living in Bangkok, Thailand and naïve to ART. Transient elastography (TE) was performed. Intrahepatic and circulating markers of inflammation and microbial translocation were quantified by ELISA and bead arrays and HIV and HBV infection quantifi..

View full abstract

University of Melbourne Researchers

Sabine Braat Author Melbourne School of Population and Global Health

Kasha Singh Author Infectious Diseases

Wei Zhao Author Infectious Diseases

Jennifer Audsley Author Infectious Diseases

Related Projects (3)

ADDRESSING THE MAJOR CHALLENGES IN HIV VACCINE AND CURE RESEARCH

HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections ea..

THE FUTURE OF HIV CARE - LONG TERM REMISSION AND ELIMINATING CO-MORBIDITIES

Despite the great successes in antiretroviral therapy (ART) in reducing HIV-associated mortality, treatment is life long and there is no cur..

HIV LATENCY PATHOGENESIS AND IMMUNITY

The development of cures, vaccines and better treatments for HIV/AIDS is an urgent global health priority. This team of seven groups in Sydn..

Grants

Awarded by National Cancer Institute, National Institutes of Health

Funding Acknowledgements

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia https://www.nhmrc.gov.au; including an NHMRC project grant (SRL, KS, MC, JA), NHMRC program grant (SRL), practitioner fellowship (SRL) and an NHMRC biomedical postgraduate scholarship (KS). This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health https://www.cancer.gov; under Contract No. 75N91019D00024 (formerly HHSN261200800001E). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.https://www.nhmrc.gov.au The Funding organisations had no role in study design, data collection and analysis, decision to publish or manuscript preparation.